RO4929097 in Treating Patients With Recurrent Invasive Gliomas
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of RO4929097 in treating
patients with recurrent invasive gliomas. RO4929097 may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth